Research programme: influenza A virus H7N9 vaccines - GlaxoSmithKline

Drug Profile

Research programme: influenza A virus H7N9 vaccines - GlaxoSmithKline

Latest Information Update: 30 Jun 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza A virus H7N9 subtype

Most Recent Events

  • 16 Jun 2016 GlaxoSmithKline withdraws a phase I trial for Influenza-A virus H7N9 subtype (Prevention) in Estonia and Hong Kong (NCT02177734)
  • 27 Jun 2014 Preclinical trials in Influenza-A virus H7N9 subtype (prevention) in United Kingdom (IM)
  • 27 Jun 2014 GlaxoSmithKline plans a phase I trial for Influenza-A virus H7N9 subtype (Prevention) in Estonia and Hong Kong (NCT02177734)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top